This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 911 |
respiratory syndrome | 728 |
severe acute | 710 |
severe covid | 539 |
mg kg | 363 |
clinical signs | 348 |
liver failure | 345 |
respiratory distress | 289 |
novel coronavirus | 287 |
coronavirus disease | 273 |
intensive care | 253 |
severe hepatitis | 246 |
mechanical ventilation | 241 |
syndrome coronavirus | 236 |
critically ill | 230 |
risk factors | 220 |
immune response | 211 |
severe cases | 206 |
respiratory failure | 203 |
falciparum malaria | 200 |
severe disease | 186 |
distress syndrome | 186 |
severe malaria | 182 |
rights reserved | 169 |
hepatic encephalopathy | 160 |
septic shock | 160 |
sars coronavirus | 155 |
renal failure | 153 |
clinical characteristics | 151 |
severe pneumonia | 147 |
ill patients | 140 |
care unit | 138 |
systematic review | 136 |
clinical trials | 136 |
ml kg | 133 |
liver disease | 132 |
kg iv | 131 |
clinical features | 129 |
disease severity | 128 |
inflammatory response | 127 |
immune responses | 123 |
sars patients | 123 |
respiratory tract | 120 |
cytokine storm | 117 |
hospitalized patients | 116 |
viral load | 114 |
blood pressure | 113 |
type i | 113 |
may also | 112 |
inflammatory cytokines | 111 |
immune system | 111 |
innate immune | 111 |
convalescent plasma | 110 |
cerebral malaria | 108 |
lung injury | 107 |
cohort study | 106 |
epithelial cells | 105 |
world health | 103 |
severe sepsis | 103 |
severe group | 98 |
severe patients | 97 |
peripheral blood | 97 |
mortality rate | 96 |
hong kong | 96 |
chronic liver | 95 |
clinical manifestations | 95 |
severe respiratory | 95 |
health organization | 94 |
clinical trial | 94 |
metabolic acidosis | 92 |
spike protein | 92 |
severe cap | 92 |
public health | 90 |
acquired pneumonia | 90 |
liver transplantation | 89 |
viral infections | 88 |
severe asthma | 87 |
increased risk | 85 |
respiratory disease | 84 |
coronavirus infection | 83 |
converting enzyme | 82 |
organ failure | 80 |
author funder | 80 |
orogastric lavage | 80 |
significantly higher | 80 |
granted medrxiv | 79 |
cord uid | 79 |
doc id | 79 |
infectious diseases | 78 |
virus infection | 78 |
pulmonary edema | 77 |
severe illness | 77 |
activated charcoal | 77 |
viral infection | 76 |
united states | 76 |
blood flow | 76 |
risk factor | 75 |
side effects | 75 |
liver function | 72 |
cov infection | 71 |
infected patients | 71 |
mental health | 70 |
abdominal pain | 70 |
acute liver | 70 |
supplemental oxygen | 70 |
chronic hepatitis | 69 |
pediatric patients | 68 |
intravenous fluids | 68 |
may occur | 67 |
patients infected | 67 |
arterial blood | 67 |
clinical course | 66 |
viral replication | 66 |
peer review | 66 |
controlled trial | 66 |
nervous system | 66 |
nitric oxide | 66 |
middle east | 65 |
respiratory rate | 65 |
kg po | 62 |
fda labels | 62 |
chest ct | 62 |
reactive protein | 62 |
nk cells | 61 |
cardiac output | 61 |
severe falciparum | 61 |
two groups | 61 |
copyright holder | 61 |
heart failure | 60 |
clinical practice | 60 |
severe ea | 60 |
east respiratory | 60 |
disseminated intravascular | 59 |
binding lectin | 59 |
severe critical | 59 |
airway obstruction | 59 |
important role | 59 |
patients treated | 58 |
retrospective cohort | 58 |
intravascular coagulation | 58 |
lactate dehydrogenase | 58 |
high risk | 58 |
lopinavir ritonavir | 58 |
bone marrow | 57 |
health care | 57 |
plasmodium falciparum | 57 |
monoclonal antibody | 57 |
lung function | 57 |
hbv infection | 57 |
adult patients | 57 |
heart rate | 57 |
liver cirrhosis | 56 |
logistic regression | 56 |
critical care | 56 |
necrosis factor | 56 |
hepatorenal syndrome | 55 |
acute lung | 55 |
randomized controlled | 54 |
mg dl | 54 |
patients may | 54 |
sars cov | 54 |
version posted | 54 |
organ dysfunction | 54 |
multiple organ | 53 |
poor prognosis | 53 |
portal hypertension | 53 |
asthma exacerbations | 53 |
icu admission | 53 |
liver diseases | 53 |
clinical symptoms | 53 |
see section | 53 |
liver injury | 53 |
higher risk | 52 |
infectious disease | 52 |
pulmonary vascular | 52 |
lymphocyte count | 51 |
adaptive immune | 51 |
red blood | 51 |
young children | 51 |
endothelial cells | 50 |
upper respiratory | 50 |
prospective study | 50 |
blood cells | 50 |
viral rna | 49 |
cell responses | 49 |
early stage | 49 |
retrospective study | 49 |
platelet count | 49 |
immune cells | 49 |
case series | 49 |
gastrointestinal tract | 49 |
randomized clinical | 48 |
critical patients | 48 |
innate immunity | 48 |
incubation period | 48 |
respiratory viruses | 48 |
central nervous | 48 |
pleural effusion | 48 |
coronavirus pneumonia | 47 |
fluid therapy | 47 |
renal function | 47 |
physical examination | 47 |
induce emesis | 47 |
animal models | 47 |
high levels | 47 |
liver cells | 47 |
pregnant women | 47 |
assessment report | 46 |
cytokine release | 46 |
high mortality | 46 |
clinical data | 46 |
factors associated | 46 |
gastrointestinal bleeding | 46 |
adverse effects | 46 |
among patients | 46 |
reuse allowed | 45 |
bacterial infection | 45 |
allowed without | 45 |
systemic inflammatory | 45 |
prothrombin time | 45 |
without permission | 45 |
present study | 44 |
perform orogastric | 44 |
tumor necrosis | 44 |
heart disease | 44 |
observational study | 44 |
severe fever | 44 |
mm hg | 43 |
acute renal | 43 |
thrombocytopenia syndrome | 43 |
hepatic failure | 43 |
severely ill | 43 |
acute phase | 43 |
body weight | 43 |
associated coronavirus | 43 |
patients admitted | 43 |
early diagnosis | 42 |
determine whether | 42 |
pulmonary disease | 42 |
administer intravenous | 42 |
within hours | 42 |
critical illness | 42 |
whenever possible | 42 |
crystalloid fluids | 42 |
central venous | 42 |
significant difference | 41 |
patients receiving | 41 |
host immune | 41 |
accepted article | 41 |
urine output | 41 |
case report | 41 |
kg hour | 41 |
statistically significant | 41 |
blood cell | 40 |
complement activation | 40 |
carbon dioxide | 40 |
foreign bodies | 40 |
respiratory symptoms | 40 |
lower respiratory | 40 |
equine asthma | 40 |
inflammatory responses | 39 |
metabolic alkalosis | 39 |
severe liver | 39 |
influenza virus | 39 |
spectrum antibiotics | 39 |
rheumatoid arthritis | 39 |
lung disease | 39 |
whole blood | 39 |
another study | 39 |
acute exacerbation | 39 |
staphylococcus aureus | 39 |
closely related | 39 |
previous studies | 39 |
ill covid | 39 |
cerebral edema | 39 |
coagulation factors | 39 |
release syndrome | 38 |
dendritic cells | 38 |
new coronavirus | 38 |
systemic inflammation | 38 |
airway inflammation | 38 |
liver cell | 38 |
blood glucose | 38 |
intracranial pressure | 38 |
inflammatory cytokine | 38 |
neutralizing antibodies | 38 |
may cause | 38 |
proinflammatory cytokines | 38 |
ace expression | 37 |
disease progression | 37 |
kg minute | 37 |
body temperature | 37 |
significant differences | 37 |
neutralizing antibody | 36 |
many cases | 36 |
blood vessels | 36 |
bronchoalveolar lavage | 36 |
independent risk | 36 |
serum levels | 36 |
recent study | 36 |
antibody responses | 36 |
endothelial cell | 36 |
macrophage activation | 36 |
airway disease | 36 |
large number | 36 |
critical covid | 35 |
blood gas | 35 |
first hours | 35 |
oxygen saturation | 35 |
patients showed | 35 |
develop severe | 35 |
clinical outcomes | 35 |
pulmonary hypertension | 35 |
white blood | 35 |
urinary tract | 34 |
clinical management | 34 |
clinical studies | 34 |
critical cases | 34 |
patients without | 34 |
social isolation | 34 |
may develop | 34 |
medrxiv preprint | 34 |
hospital mortality | 34 |
fungal infection | 34 |
nucleic acid | 34 |
foreign body | 34 |
inflammatory reaction | 34 |
severe infection | 34 |
supportive care | 33 |
intravenous crystalloid | 33 |
significantly increased | 33 |
natural killer | 33 |
intravenous immunoglobulin | 33 |
controlled trials | 33 |
pulse oximetry | 33 |
significantly lower | 33 |
posted may | 33 |
severe community | 33 |
tract infection | 33 |
case reports | 33 |
antiviral drugs | 33 |
frozen plasma | 33 |
pulmonary embolism | 33 |
i ifn | 33 |
disease control | 33 |
tidal volume | 33 |
poor outcome | 32 |
cell count | 32 |
adverse events | 32 |
care workers | 32 |
maternal morbidity | 32 |
drotrecogin alfa | 32 |
mortality rates | 32 |
cause severe | 32 |
fatality rate | 32 |
icu patients | 32 |
several studies | 32 |
may result | 32 |
may lead | 32 |
kg day | 32 |
endotracheal intubation | 31 |
intravenous fluid | 31 |
inflammatory mediators | 31 |
fresh frozen | 31 |
infected pneumonia | 31 |
chain reaction | 31 |
pandemic influenza | 31 |
general anesthesia | 31 |
bacterial infections | 31 |
survival rate | 31 |
plasminogen activator | 31 |
type hepatitis | 31 |
hospital admission | 31 |
also found | 31 |
clinical improvement | 31 |
one study | 31 |
activation syndrome | 31 |
diabetes mellitus | 30 |
diagnostic criteria | 30 |
limited settings | 30 |
treatment consists | 30 |
pediatric intensive | 30 |
hepatitis patients | 30 |
response syndrome | 30 |
also reported | 30 |
invasive mechanical | 30 |
obstructive pulmonary | 30 |
one patient | 30 |
african children | 30 |
included studies | 30 |
immunomodulatory therapy | 30 |
elevated levels | 30 |
emergency care | 30 |
serum albumin | 30 |
hemophagocytic lymphohistiocytosis | 29 |
soft tissue | 29 |
regression analysis | 29 |
respiratory syncytial | 29 |
commonly used | 29 |
severe dengue | 29 |
cytokine levels | 29 |
blood samples | 29 |
complement system | 29 |
cardiovascular disease | 29 |
gene expression | 29 |
plasma therapy | 29 |
nk cell | 29 |
within days | 29 |
underlying disease | 29 |
oxygen therapy | 29 |
early phase | 29 |
clinical presentation | 29 |
differential diagnosis | 29 |
liver damage | 28 |
mild cases | 28 |
control group | 28 |
cytokine production | 28 |
chronic obstructive | 28 |
respiratory infections | 28 |
avian influenza | 28 |
lymphocyte ratio | 28 |
intravenous catheter | 28 |
i interferon | 28 |
years old | 28 |
oxygen delivery | 28 |
prognostic factors | 28 |
syncytial virus | 28 |
diagnostic tests | 28 |
scoring system | 28 |
mechanically ventilated | 28 |
pidd patients | 28 |
severe maternal | 28 |
kupffer cells | 28 |
healthy controls | 28 |
human coronavirus | 27 |
care units | 27 |
femoral head | 27 |
underlying diseases | 27 |
coronavirus associated | 27 |
kawasaki disease | 27 |
case fatality | 27 |
polymerase chain | 27 |
monoclonal antibodies | 27 |
early stages | 27 |
viral shedding | 27 |
severe leukopenia | 27 |
confirmed cases | 27 |
clotting factors | 27 |
blood ammonia | 27 |
partial pressure | 27 |
severe rd | 27 |
serum creatinine | 27 |
higher levels | 27 |
significantly associated | 27 |
patients hospitalized | 27 |
respiratory alkalosis | 26 |
sterile saline | 26 |
gas exchange | 26 |
hepatic cirrhosis | 26 |
may contribute | 26 |
mean age | 26 |
blood volume | 26 |
may require | 26 |
th cells | 26 |
may include | 26 |
apache ii | 26 |
increased levels | 26 |
systemic circulation | 26 |
cardiac dysrhythmias | 26 |
extracellular traps | 26 |
effective treatment | 26 |
brain edema | 26 |
mild covid | 26 |
recurrent airway | 26 |
make sure | 26 |
amino acid | 26 |
immune function | 26 |
viral hepatitis | 26 |
human coronaviruses | 26 |
international license | 26 |
endemic areas | 25 |
molecular weight | 25 |
viral clearance | 25 |
viral entry | 25 |
respiratory system | 25 |
severe infections | 25 |
currently available | 25 |
two patients | 25 |
upper airway | 25 |
randomized trial | 25 |
made available | 25 |
sample size | 25 |
laboratory tests | 25 |
intestinal epithelial | 25 |
saline solution | 25 |
long term | 25 |
iv cri | 25 |
hpa axis | 25 |
vitro studies | 25 |
aspiration pneumonia | 25 |
statistical analysis | 25 |
syndrome virus | 25 |
data suggest | 25 |
cerebrospinal fluid | 25 |
type ii | 25 |
high fever | 25 |
urinary catheter | 25 |
rhesus macaques | 25 |
local anesthetic | 25 |
within weeks | 25 |
neutrophil extracellular | 25 |
disease caused | 25 |
median age | 25 |
alveolar damage | 25 |
many patients | 25 |
care medicine | 25 |
hospitalized covid | 24 |
receptor antagonist | 24 |
fatal cases | 24 |
gastrointestinal symptoms | 24 |
coronavirus spike | 24 |
moderate ea | 24 |
cell types | 24 |
amino acids | 24 |
neurological diseases | 24 |
may play | 24 |
smooth muscle | 24 |
protective immunity | 24 |
computed tomography | 24 |
lymph nodes | 24 |
renal perfusion | 24 |
endotracheal tube | 24 |
fluid resuscitation | 24 |
cardiac arrest | 24 |
streptococcus pneumoniae | 24 |
spike glycoprotein | 23 |
signs associated | 23 |
diaphragmatic hernia | 23 |
angiotensin ii | 23 |
host cells | 23 |
antibiotic therapy | 23 |
thoracic radiographs | 23 |
therapy may | 23 |
cardiac surgery | 23 |
underlying cause | 23 |
pulmonary interstitial | 23 |
clinical outcome | 23 |
maintain hydration | 23 |
clinical severity | 23 |
lung pathology | 23 |
negative bacteria | 23 |
shock syndrome | 23 |
kidney disease | 23 |
electrolyte abnormalities | 23 |
blood count | 23 |
laboratory findings | 23 |
viral particles | 23 |
ill children | 23 |
growth factor | 23 |
medical records | 23 |
small number | 23 |
children patients | 23 |
retrospective analysis | 23 |
small intestine | 23 |
receptor binding | 22 |
recent years | 22 |
brain barrier | 22 |
ventricular dysrhythmias | 22 |
anterior chamber | 22 |
aseptically scrub | 22 |
within minutes | 22 |
cell damage | 22 |
lactic acidosis | 22 |
ng ml | 22 |
ml min | 22 |
severe vs | 22 |
viral loads | 22 |
severe influenza | 22 |
exchange transfusion | 22 |
control study | 22 |
confidence interval | 22 |
oxidative stress | 22 |
severe sars | 22 |
infected cells | 22 |
crystalloid fluid | 22 |
cirrhotic patients | 22 |
normal range | 22 |
significantly different | 22 |
blood products | 22 |
emergency department | 22 |
blood coagulation | 22 |
fungal infections | 22 |
cell entry | 22 |
severe adenovirus | 22 |
congestive heart | 22 |
mild patients | 22 |
emerging infectious | 21 |
plasmodium vivax | 21 |
ventilatory support | 21 |
antiviral therapy | 21 |
drug administration | 21 |
body mass | 21 |
host cell | 21 |
pathological changes | 21 |
hypersensitivity reactions | 21 |
renal tubular | 21 |
vascular resistance | 21 |
tissue damage | 21 |
angiotensin converting | 21 |
vascular endothelial | 21 |
vivax malaria | 21 |
pulmonary function | 21 |
cns excitation | 21 |
general population | 21 |
catheter placement | 21 |
prognostic value | 21 |
muscle tremors | 21 |
multiple sclerosis | 21 |
atopic dermatitis | 21 |
climate change | 21 |
odds ratio | 21 |
like disease | 21 |
vascular dilatation | 21 |
acute hepatitis | 21 |
functional receptor | 21 |
also observed | 21 |
wide range | 21 |
lung damage | 21 |
mucous membranes | 21 |
cell response | 21 |
positively correlated | 21 |
stem cell | 21 |
disease process | 21 |
aspartate aminotransferase | 20 |
pao fio | 20 |
vaccine development | 20 |
control seizures | 20 |
inflammatory syndrome | 20 |
factor viii | 20 |
new york | 20 |
developing severe | 20 |
mean arterial | 20 |
coagulation dysfunction | 20 |
coronavirus infections | 20 |
weight loss | 20 |
common clinical | 20 |
west nile | 20 |
spinal cord | 20 |
anaphylactic reactions | 20 |
cell surface | 20 |
combination therapy | 20 |
moderate covid | 20 |
kidney injury | 20 |
refractory ascites | 20 |
hepatopulmonary syndrome | 20 |
small amount | 20 |
urinary bladder | 20 |
pneumonia group | 20 |
high level | 20 |
human monoclonal | 20 |
toxicity include | 20 |
also occur | 20 |
kg sq | 20 |
southern china | 20 |
rna polymerase | 20 |
multivariate analysis | 20 |
ace receptors | 20 |
high dose | 20 |
class ii | 20 |
sodium bicarbonate | 20 |
bile duct | 20 |
one case | 20 |
even though | 20 |
leukocyte count | 20 |
virus infections | 20 |
oral administration | 20 |
first case | 20 |
increased significantly | 20 |
made based | 20 |
infected individuals | 20 |
fluid bolus | 20 |
infection control | 20 |
massive necrosis | 20 |
liver dysfunction | 20 |
head trauma | 20 |
small intestinal | 19 |
may reveal | 19 |
capillary refill | 19 |
gastroprotectant drugs | 19 |
study showed | 19 |
phase iii | 19 |
analgesic drugs | 19 |
ethylene glycol | 19 |
study clinical | 19 |
platelet transfusion | 19 |
allergic reactions | 19 |
may appear | 19 |
study also | 19 |
serum potassium | 19 |
fulminant hepatitis | 19 |
blood gases | 19 |
protease inhibitors | 19 |
may present | 19 |
zika virus | 19 |
reactive oxygen | 19 |
dysfunction syndrome | 19 |
adaptive immunity | 19 |
remains unclear | 19 |
broad spectrum | 19 |
immunomodulatory therapies | 19 |
nile virus | 19 |
least one | 19 |
ct scan | 19 |
bridging necrosis | 19 |
severe pulmonary | 19 |
less severe | 19 |
chest pain | 19 |
disease onset | 19 |
protease inhibitor | 19 |
drug manual | 19 |
lower airway | 19 |
airway pressure | 19 |
like receptor | 19 |
may increase | 19 |
stage liver | 19 |
respiratory illness | 19 |
cap group | 19 |
primary immunodeficiency | 19 |
diffuse alveolar | 19 |
nonsteroidal antiinflammatory | 19 |
peritoneal dialysis | 19 |
first week | 19 |
refill time | 19 |
adverse reactions | 19 |
intravenous quinine | 18 |
south korea | 18 |
arterial oxygen | 18 |
blood transfusion | 18 |
ventricular tachycardia | 18 |
acute onset | 18 |
spectrum antiviral | 18 |
severe lung | 18 |
descriptive study | 18 |
previously healthy | 18 |
factor vii | 18 |
liver biopsy | 18 |
moderate cases | 18 |
replacement therapy | 18 |
laboratory parameters | 18 |
day mortality | 18 |
toxic potential | 18 |
clinical diagnosis | 18 |
clinical picture | 18 |
upper airways | 18 |
failure caused | 18 |
complete blood | 18 |
neurological symptoms | 18 |
patients will | 18 |
fatal outcome | 18 |
antibody response | 18 |
infection may | 18 |
full text | 18 |
mild ea | 18 |
mouse model | 18 |
susceptibility testing | 18 |
lymphocyte counts | 18 |
pilot study | 18 |
ema assessment | 18 |
congenital heart | 18 |
organ damage | 18 |
blood group | 18 |
like receptors | 18 |
corticosteroid therapy | 18 |
also associated | 18 |
kupffer cell | 18 |
lavage fluid | 18 |
elderly patients | 18 |
better understanding | 18 |
common causes | 18 |
lactic acid | 18 |
sars virus | 18 |
nlrp inflammasome | 18 |
pediatric covid | 18 |
cell membrane | 18 |
immunocompromised patients | 18 |
recombinant human | 18 |
might also | 18 |
ace receptor | 18 |
rna viruses | 18 |
rate infusion | 18 |
renal dysfunction | 18 |
differential diagnoses | 18 |
constant rate | 18 |
jak inhibitors | 18 |
clinical progression | 18 |
disease course | 18 |
sore throat | 18 |
antiviral activity | 18 |
binding protein | 18 |
transmission dynamics | 18 |
receptor ace | 18 |
intercostal space | 18 |
corticosteroid treatment | 18 |
enteral feeding | 17 |
intravenous artesunate | 17 |
absolute lymphocyte | 17 |
host defense | 17 |
short term | 17 |
clinical variables | 17 |
birth weight | 17 |
chronic severe | 17 |
cns depression | 17 |
much higher | 17 |
see table | 17 |
portal vein | 17 |
electron microscopy | 17 |
igg antibodies | 17 |
febrile illness | 17 |
virus disease | 17 |
toxic dose | 17 |
adult inpatients | 17 |
serine protease | 17 |
performed using | 17 |
healthy adults | 17 |
escherichia coli | 17 |
intraocular pressure | 17 |
fibrin degradation | 17 |
cell culture | 17 |
test results | 17 |
host factors | 17 |
important factor | 17 |
complicated malaria | 17 |
severe systemic | 17 |
vein thrombosis | 17 |
categorical variables | 17 |
study conducted | 17 |
catheter hub | 17 |
may help | 17 |
human transmission | 17 |
acute kidney | 17 |
high incidence | 17 |
important roles | 17 |
rna virus | 17 |
mbl deficiency | 17 |
informed consent | 17 |
advanced age | 17 |
lyme disease | 17 |
hyperferritinemic syndrome | 17 |
natural history | 17 |
allergic diseases | 17 |
asthma exacerbation | 17 |
loading dose | 17 |
high doses | 17 |
small animal | 17 |
class i | 17 |
dengue shock | 17 |
hypovolemic shock | 17 |
healthcare workers | 17 |
respiratory function | 17 |
stem cells | 17 |
vaccine candidates | 17 |
oxygen species | 17 |
treatment strategies | 17 |
study group | 17 |
animal model | 17 |
protective role | 17 |
china clinical | 17 |
occur within | 17 |
oncotic pressure | 17 |
higher incidence | 17 |
symptom onset | 17 |
warm water | 17 |
inflammatory airway | 17 |
partial thromboplastin | 17 |
sars cases | 17 |
three patients | 17 |
high frequency | 17 |
relapsing fever | 17 |
first days | 16 |
cell carcinoma | 16 |
affected area | 16 |
two cases | 16 |
cardiogenic shock | 16 |
missing data | 16 |
widely used | 16 |
may reduce | 16 |
authors declare | 16 |
immune activation | 16 |
reduce mortality | 16 |
signs may | 16 |
patients died | 16 |
immunodeficiency virus | 16 |
low levels | 16 |
overall mortality | 16 |
candida albicans | 16 |
human airway | 16 |
mitochondrial dysfunction | 16 |
serum bilirubin | 16 |
venous blood | 16 |
atrial fibrillation | 16 |
different clinical | 16 |
recently published | 16 |
membrane oxygenation | 16 |
hiv infection | 16 |
person transmission | 16 |
intestinal mucosa | 16 |
fluid diuresis | 16 |
cardiac disease | 16 |
renal disease | 16 |
multiple organs | 16 |
vascular access | 16 |
nkt cells | 16 |
seasonal influenza | 16 |
primary cause | 16 |
clinical findings | 16 |
significant increase | 16 |
bacterial translocation | 16 |
tract infections | 16 |
tap water | 16 |
artificial liver | 16 |
healthy individuals | 16 |
patients developed | 16 |
potential therapeutic | 16 |
red cell | 16 |
will help | 16 |
metabolic disorders | 16 |
predictive value | 16 |
studies showed | 16 |
fi brosis | 16 |
cell counts | 16 |
association study | 16 |
type iii | 16 |
specific antibody | 16 |
national health | 16 |
exclusion criteria | 16 |
older age | 16 |
future studies | 16 |
life cycle | 16 |
arterial pressure | 16 |
immune evasion | 16 |
pulmonary artery | 16 |
antiinflammatory drugs | 16 |
elevated lactate | 16 |
standard treatment | 16 |
cov spike | 16 |
multivariate logistic | 16 |
bacterial peritonitis | 16 |
granulation tissue | 16 |
poor outcomes | 16 |
inflammatory diseases | 16 |
failure patients | 16 |
among children | 16 |
united kingdom | 16 |
direct contact | 16 |
dynamic changes | 16 |
antibody titers | 16 |
creative commons | 16 |
severe symptoms | 16 |
emergency use | 16 |
spotted fever | 16 |
prognostic significance | 16 |
alanine aminotransferase | 16 |
prospective observational | 15 |
abo blood | 15 |
significantly reduced | 15 |
protective effect | 15 |
late stage | 15 |
structural proteins | 15 |
severe coronavirus | 15 |
primary care | 15 |
mortality among | 15 |
include vomiting | 15 |
ace protein | 15 |
high viral | 15 |
antimicrobial peptides | 15 |
spontaneous bacterial | 15 |
may become | 15 |
mesenchymal stem | 15 |
prism score | 15 |
several days | 15 |
parenteral nutrition | 15 |
clinical benefit | 15 |
base imbalance | 15 |
every hours | 15 |
airway epithelial | 15 |
influenza pandemic | 15 |
large amounts | 15 |
severe type | 15 |
human ace | 15 |
use authorization | 15 |
bolus therapy | 15 |
systemic infection | 15 |
global health | 15 |
extension tubing | 15 |
multisystem inflammatory | 15 |
yellow fever | 15 |
dependent rna | 15 |
renal replacement | 15 |
common symptoms | 15 |
chronic lung | 15 |
intravenous infusion | 15 |
status epilepticus | 15 |
binding domain | 15 |
meq kg | 15 |
reverse transcription | 15 |
angiotensin system | 15 |
secondary hlh | 15 |
patients usually | 15 |
hbv replication | 15 |
autoimmune diseases | 15 |
southeast asia | 15 |
urea nitrogen | 15 |
intestinal mucosal | 15 |
severe anaemia | 15 |
pcr assays | 15 |
cell activation | 15 |
upper gastrointestinal | 15 |
serum sodium | 15 |
interim guidance | 15 |
treatment group | 15 |
drug name | 15 |
drug resistance | 15 |
hemolytic anemia | 15 |
infectious agents | 15 |
posted march | 15 |
higher mortality | 15 |
activated partial | 15 |
syndrome clinical | 15 |
urgent need | 15 |
mixed viral | 15 |
secondary infections | 15 |
causes severe | 15 |
sars outbreak | 15 |
cardiac injury | 15 |
respiratory acidosis | 15 |
abdominal cavity | 15 |
cancer drug | 15 |
common cause | 15 |
biliary tract | 15 |
secondary infection | 15 |
cell death | 15 |
mononuclear cells | 15 |
ct data | 15 |
acute severe | 15 |
lymphocyte subsets | 15 |
continuous variables | 15 |
coagulation factor | 15 |
inflammatory markers | 15 |
capillary permeability | 15 |
red cells | 15 |
taking care | 15 |
pressure ventilation | 15 |
respiratory pattern | 15 |
sputum samples | 15 |
extracorporeal membrane | 15 |
viral pneumonia | 15 |
reported cases | 15 |
pneumonia caused | 15 |
functional exhaustion | 15 |
human disease | 15 |
increased mortality | 15 |
administer supplemental | 15 |
ventricular fibrillation | 15 |
human infection | 15 |
exact test | 15 |
adults hospitalized | 15 |
bacterial co | 15 |
strongly associated | 14 |
also known | 14 |
stimulating factor | 14 |
active ingredient | 14 |
induced acute | 14 |
inflammatory cells | 14 |
clinical manifestation | 14 |
total body | 14 |
pediatric icu | 14 |
ct images | 14 |
studies demonstrated | 14 |
childhood asthma | 14 |
vaccine candidate | 14 |
immune dysregulation | 14 |
acute hepatic | 14 |
successfully treated | 14 |
human immunodeficiency | 14 |
base balance | 14 |
analysis showed | 14 |
renal blood | 14 |
respiratory infection | 14 |
patients also | 14 |
large amount | 14 |
ct findings | 14 |
anion gap | 14 |
patients aged | 14 |
inborn errors | 14 |
macrophage responses | 14 |
cd cd | 14 |
burn injury | 14 |
elevated serum | 14 |
injection site | 14 |
dna vaccine | 14 |
emergency treatment | 14 |
affected horses | 14 |
filtration rate | 14 |
total number | 14 |
abdominal radiographs | 14 |
community outbreak | 14 |
wide association | 14 |
chest radiograph | 14 |
two different | 14 |
less common | 14 |
data collection | 14 |
hospital discharge | 14 |
administer gastroprotectant | 14 |
human lung | 14 |
plasma exchange | 14 |
blood urea | 14 |
ventilation may | 14 |
paediatric intensive | 14 |
treated patients | 14 |
emerging infections | 14 |
years ago | 14 |
coagulation system | 14 |
recovered patients | 14 |
cellular immune | 14 |
virus replication | 14 |
term outcome | 14 |
intrahepatic cholestasis | 14 |
assisted ventilation | 14 |
significant risk | 14 |
th cytokine | 14 |
immune cell | 14 |
antiviral drug | 14 |
genetic variants | 14 |
necrotizing pneumonia | 14 |
long time | 14 |
inflammatory cell | 14 |
therapeutic strategies | 14 |
clinical significance | 14 |
pattern recognition | 14 |
recent studies | 14 |
ear canal | 14 |
dry cough | 14 |
total bilirubin | 14 |
multiorgan failure | 14 |
social distancing | 14 |
positive pressure | 14 |
case management | 14 |
control measures | 14 |
kg body | 14 |
immune complexes | 14 |
independently associated | 14 |
function tests | 14 |
oxygen supplementation | 14 |
respiratory secretions | 14 |
chinese center | 14 |
promoter region | 14 |
function testing | 14 |
malarial disease | 14 |
tissue perfusion | 14 |
developed severe | 14 |
glomerular filtration | 14 |
respiratory status | 14 |
therapeutic efficacy | 14 |
fluid volume | 14 |
cirrhosis patients | 14 |
chronic pain | 14 |
cardiac failure | 14 |
successful treatment | 14 |
time rt | 14 |
deep learning | 14 |
clinical presentations | 14 |
leukocytes ml | 14 |
study using | 14 |
coronavirus replication | 14 |
eosinophilic asthma | 14 |
lactate levels | 14 |
ct scans | 14 |
specific igg | 14 |
study involving | 14 |
premature infants | 14 |
patient may | 14 |
tumour necrosis | 14 |
int csr | 14 |
gestational age | 14 |
activated protein | 14 |
two studies | 14 |
different stages | 14 |
infusion reactions | 14 |
future research | 14 |
key role | 14 |
critical progression | 14 |
fresh whole | 14 |
pulmonary consolidation | 14 |
family members | 13 |
cytokine profiles | 13 |
innate lymphoid | 13 |
good prognosis | 13 |
human respiratory | 13 |
patients often | 13 |
albumin levels | 13 |
gas analysis | 13 |
clinical study | 13 |
data analysis | 13 |
brain tissue | 13 |
cap patients | 13 |
liver tissue | 13 |
red rubber | 13 |
tissue distribution | 13 |
cellular immunity | 13 |
saharan africa | 13 |
wound healing | 13 |
anaphylactic reaction | 13 |
mean duration | 13 |
varying degrees | 13 |
supplementary table | 13 |
membrane fusion | 13 |
genome sequence | 13 |
young adults | 13 |
venous pressure | 13 |
liver enzymes | 13 |
poor performance | 13 |
atypical pneumonia | 13 |
primary infection | 13 |
antiemetic drugs | 13 |
fluid management | 13 |
consensus statement | 13 |
age group | 13 |
adhesion molecule | 13 |
deep vein | 13 |
venous catheter | 13 |
disease clinical | 13 |
imported malaria | 13 |
repeated doses | 13 |
serological tests | 13 |
kg im | 13 |
disease patients | 13 |
induced liver | 13 |
patients diagnosed | 13 |
animal patients | 13 |
thoracostomy tube | 13 |
intestinal flora | 13 |
findings suggest | 13 |
lung tissue | 13 |
affected individuals | 13 |
solid organ | 13 |
coagulation parameters | 13 |
weight heparin | 13 |
mild rd | 13 |
liver transplant | 13 |
phase i | 13 |
blood circulation | 13 |
hospital stay | 13 |
density shadows | 13 |
core promoter | 13 |
allergic disease | 13 |
real time | 13 |
year old | 13 |
severe complications | 13 |
sars infection | 13 |
hps patients | 13 |
secondary hemophagocytic | 13 |
administer activated | 13 |
transjugular intrahepatic | 13 |
systemic levels | 13 |
increased susceptibility | 13 |
significant reduction | 13 |
prospective cohort | 13 |
uncomplicated malaria | 13 |
highly pathogenic | 13 |
clinical disease | 13 |
phase trial | 13 |
plasma levels | 13 |
increased respiratory | 13 |
osmotic pressure | 13 |
organ transplantation | 13 |
ml syringe | 13 |
worse outcome | 13 |
free radical | 13 |
average age | 13 |
older adults | 13 |
intrahepatic portosystemic | 13 |
crucial role | 13 |
prowess trial | 13 |
clinical specimens | 13 |
cells may | 13 |
inhaled corticosteroids | 13 |
gauge needle | 13 |
myocardial infarction | 13 |
uncomplicated falciparum | 13 |
times higher | 13 |
tissue factor | 13 |
included patients | 13 |
killer cells | 13 |
mortality due | 13 |
laboratory diagnosis | 13 |
infected mice | 13 |
coronavirus rna | 13 |
type patients | 13 |
sars pathogenesis | 13 |
clinical treatment | 13 |
thromboplastin time | 13 |
csr sars | 13 |
chronic respiratory | 13 |
intravascular hemolysis | 13 |
sodium chloride | 13 |
minimal hepatic | 13 |
tissue plasminogen | 13 |
within months | 13 |
urethral obstruction | 13 |
packed rbcs | 13 |
severe outcomes | 13 |
lung cancer | 13 |
extremely severe | 13 |
baseline characteristics | 13 |
study found | 13 |
transplant recipients | 13 |
high prevalence | 13 |
adult respiratory | 13 |
antiviral treatment | 13 |
vital signs | 13 |
acute covid | 13 |
near miss | 13 |
different types | 13 |
known antidote | 13 |
high rate | 13 |
host response | 13 |
cell subsets | 13 |
nutritional support | 13 |
recovery phase | 13 |
foreign object | 13 |
relatively low | 13 |
base status | 13 |
severe manifestations | 13 |
tidal volumes | 13 |
fast respiratory | 13 |
also cause | 13 |
largely supportive | 13 |
organ systems | 13 |
previously described | 12 |
critical role | 12 |
pulmonary capillaries | 12 |
asthmatic patients | 12 |
kidney function | 12 |
without severe | 12 |
treating patients | 12 |
disease may | 12 |
pulmonary infiltrates | 12 |
proinflammatory cytokine | 12 |
treatment protocol | 12 |
allergic asthma | 12 |
per minute | 12 |
cp therapy | 12 |
involving patients | 12 |
phase ii | 12 |
uric acid | 12 |
north america | 12 |
hla class | 12 |
confirmed covid | 12 |
will need | 12 |
veterinary medicine | 12 |
aged years | 12 |
laryngeal paralysis | 12 |
morbid neurological | 12 |
copy number | 12 |
minute iv | 12 |
small sample | 12 |
creatine kinase | 12 |
second week | 12 |
intrapulmonary vascular | 12 |
psoriatic arthritis | 12 |
several factors | 12 |
several limitations | 12 |
atrioventricular block | 12 |
serum il | 12 |
eosinophil counts | 12 |
related coronavirus | 12 |
serious complications | 12 |
spider nevus | 12 |
body surface | 12 |
oxygen requirement | 12 |
multicenter study | 12 |
severe equine | 12 |
task force | 12 |
small amounts | 12 |
preliminary report | 12 |
study population | 12 |
human mab | 12 |
compassionate use | 12 |
patient discomfort | 12 |
seven days | 12 |
glucocorticoid therapy | 12 |
standard deviation | 12 |
might lead | 12 |
dimer levels | 12 |
ebola virus | 12 |
treatment guidelines | 12 |
antithrombin iii | 12 |
significant correlation | 12 |
pneumonia outbreak | 12 |
controlled study | 12 |
short period | 12 |
mass index | 12 |
cardiovascular system | 12 |
cytokine responses | 12 |
median duration | 12 |
convalescent sera | 12 |
confirmed sars | 12 |
target cells | 12 |
contact tracing | 12 |
time pcr | 12 |
thrombotic complications | 12 |
initial treatment | 12 |
immune compromised | 12 |
maternal mortality | 12 |
elizabethan collar | 12 |
early detection | 12 |
bacterial sepsis | 12 |
human cerebral | 12 |
cohort studies | 12 |
patients requiring | 12 |
lower airways | 12 |
balamuthia mandrillaris | 12 |
ventilated patients | 12 |
may provide | 12 |
ii score | 12 |
electronic medical | 12 |
autoimmune disease | 12 |
new virus | 12 |
right atrium | 12 |
also contribute | 12 |
units kg | 12 |
human body | 12 |
storm syndrome | 12 |
will provide | 12 |
medical management | 12 |
platelet counts | 12 |
cell therapy | 12 |
borrelia miyamotoi | 12 |
hemorrhagic fever | 12 |
viral proteins | 12 |
von willebrand | 12 |
first line | 12 |
epithelial cell | 12 |
stimulated gene | 12 |
virus transmission | 12 |
competing interests | 12 |
surgical intervention | 12 |
low molecular | 12 |
chronic kidney | 12 |
often associated | 12 |
specific antibodies | 12 |
impaired consciousness | 12 |
health emergency | 12 |
study reported | 12 |
brain injury | 12 |
minimum database | 12 |
clipped area | 12 |
antiviral effects | 12 |
dermal exposure | 12 |
non critical | 12 |
cases may | 12 |
icu syndrome | 12 |
community acquired | 12 |
life support | 12 |
cell epitopes | 12 |
interferon response | 12 |
initial symptom | 12 |
risk patients | 12 |
tracheal mucus | 12 |
valentine leukocidin | 12 |
host responses | 12 |
toxic effects | 12 |
high rates | 12 |
ventilation blood | 12 |
high morbidity | 12 |
lower levels | 12 |
fio ratio | 12 |
commercially available | 12 |
type inflammation | 12 |
atrial standstill | 12 |
gene promoter | 12 |
myocardial injury | 12 |
primary disease | 12 |
cell immunity | 12 |
gold standard | 12 |
human asthma | 11 |
statistical significance | 11 |
patient characteristics | 11 |
mild disease | 11 |
therapeutic option | 11 |
depressive symptoms | 11 |
cell dysfunction | 11 |
will require | 11 |
bronchial epithelial | 11 |
accessory proteins | 11 |
factor receptor | 11 |
lung parenchyma | 11 |
inflammatory drugs | 11 |
mbl gene | 11 |
critical group | 11 |
pulmonary aspergillosis | 11 |
rapid diagnosis | 11 |
dependent enhancement | 11 |
uncontrolled asthma | 11 |
mg days | 11 |
pulmonary arterial | 11 |
fi rst | 11 |
brain swelling | 11 |
observational studies | 11 |
electrolyte imbalance | 11 |
clinical efficacy | 11 |
colloid fluids | 11 |
respiratory insufficiency | 11 |
idiopathic arthritis | 11 |
also lead | 11 |
influenza viruses | 11 |
pleural space | 11 |
confluent necrosis | 11 |
respiratory burst | 11 |
severe stage | 11 |
five days | 11 |
main clinical | 11 |
arterial partial | 11 |
supplementary material | 11 |
regular insulin | 11 |
age groups | 11 |
including sars | 11 |
including severe | 11 |
oxygen supply | 11 |
small molecule | 11 |
antiviral agent | 11 |
molecular mechanisms | 11 |
common patients | 11 |
first step | 11 |
cardiopulmonary arrest | 11 |
contact layer | 11 |
heartland virus | 11 |
chronic renal | 11 |
anesthetic drugs | 11 |
mechanisms underlying | 11 |
signal transduction | 11 |
may reflect | 11 |
ingestion includes | 11 |
reperfusion injury | 11 |
appropriate treatment | 11 |
healthy children | 11 |
symptoms may | 11 |
working group | 11 |
catheter site | 11 |
hepatitis virus | 11 |
influenza infection | 11 |
nursing home | 11 |
protein kinase | 11 |
medical history | 11 |
patchy shadows | 11 |
primary liver | 11 |
easily accessible | 11 |
resource utilization | 11 |
highly effective | 11 |
mast cells | 11 |
coagulation cascade | 11 |
blood smear | 11 |
respiratory covid | 11 |
nosocomial infection | 11 |
i interferons | 11 |
affected animals | 11 |
well tolerated | 11 |
lymphoid cells | 11 |
health checkup | 11 |
predisposing factors | 11 |
fatal covid | 11 |
smoke inhalation | 11 |
abnormal coagulation | 11 |
nucleocapsid protein | 11 |
janus kinase | 11 |
platelet function | 11 |
group i | 11 |
asthma control | 11 |
gastric decontamination | 11 |
animals may | 11 |
humoral immune | 11 |
evidence suggests | 11 |
toxic substances | 11 |
outcomes among | 11 |
sudden onset | 11 |
may induce | 11 |
decreased significantly | 11 |
virus entry | 11 |
reactions occurred | 11 |
vena cava | 11 |
bat origin | 11 |
juvenile idiopathic | 11 |
medical staff | 11 |
endoplasmic reticulum | 11 |
arterial hypertension | 11 |
severe hepatic | 11 |
water retention | 11 |
abdominal ultrasound | 11 |
results showed | 11 |
developing countries | 11 |
syndrome severe | 11 |
will also | 11 |
intravascular volume | 11 |
open reading | 11 |
side effect | 11 |
continuous infusion | 11 |
thoracic society | 11 |
health outcomes | 11 |
controlled clinical | 11 |
immune dysfunction | 11 |
bleeding tendency | 11 |
treatment options | 11 |
signs include | 11 |
treatment strategy | 11 |
domestic animals | 11 |
healthy horses | 11 |
inclusion criteria | 11 |
genetic variation | 11 |
subcutaneous emphysema | 11 |
term management | 11 |
serum biochemistry | 11 |
patients compared | 11 |
scoring systems | 11 |
participants receiving | 11 |
decompensated liver | 11 |
rhesus macaque | 11 |
four patients | 11 |
skin lesions | 11 |
respiratory viral | 11 |
high blood | 11 |
intestinal obstruction | 11 |
therapeutic intervention | 11 |
laboratory results | 11 |
herpes simplex | 11 |
dead space | 11 |
drug interactions | 11 |
pd deficiency | 11 |
east asia | 11 |
cooling measures | 11 |
sepsis patients | 11 |
oral transmission | 11 |
bal fluid | 11 |
pulmonary fibrosis | 11 |
cell rna | 11 |
situ hybridization | 11 |
chronic hbv | 11 |
causative agent | 11 |
clinical research | 11 |
pulmonary contusions | 11 |
nasal discharge | 11 |
readily available | 11 |
requiring mechanical | 11 |
major outbreak | 11 |
animal studies | 11 |
aggressive treatment | 11 |
coagulation tests | 11 |
cleavage site | 11 |
factor xiii | 11 |
respiratory diseases | 11 |
low dose | 11 |
glucose levels | 11 |
plr value | 11 |
million people | 11 |
cytokine response | 11 |
transgenic mice | 11 |
respiratory support | 11 |
skin rash | 11 |
vast majority | 10 |
temporary tracheostomy | 10 |
clinically proven | 10 |
current evidence | 10 |
hepatocyte necrosis | 10 |
recognition receptors | 10 |
factors may | 10 |
sequence analysis | 10 |
ex vivo | 10 |
organ perfusion | 10 |
related reactions | 10 |
important lessons | 10 |
degradation products | 10 |
often accompanied | 10 |
esophageal irritation | 10 |
maternal near | 10 |
flapping tremor | 10 |
international normalized | 10 |
central role | 10 |
intestinal tract | 10 |
also may | 10 |
gastrointestinal hemorrhage | 10 |
therapeutic target | 10 |
associated sars | 10 |
blood culture | 10 |
early warning | 10 |
free water | 10 |
severe anemia | 10 |
specific treatment | 10 |
significantly elevated | 10 |
young covid | 10 |
normalized ratio | 10 |
laboratory testing | 10 |
serum lactate | 10 |
initial dose | 10 |
probable sars | 10 |
study design | 10 |
mild moderate | 10 |
guangdong province | 10 |
platelet aggregation | 10 |
cell infection | 10 |
early recognition | 10 |
immunoglobulin therapy | 10 |
pg ml | 10 |
induced illness | 10 |
also important | 10 |
patients survived | 10 |
independent predictors | 10 |
drugs used | 10 |
univariate analysis | 10 |
per se | 10 |
tick bites | 10 |
fluid loss | 10 |
adult covid | 10 |
coagulation disorders | 10 |
stroke volume | 10 |
postural changes | 10 |
hbv carriers | 10 |
pulmonary infection | 10 |
may progress | 10 |
serum sickness | 10 |
respiratory samples | 10 |
hbv quasispecies | 10 |
accurate diagnosis | 10 |
potential role | 10 |
like protease | 10 |
potent neutralization | 10 |
systemic juvenile | 10 |
potential risks | 10 |
new insights | 10 |
tissue injury | 10 |
ascertainment rate | 10 |
three days | 10 |
intracranial hemorrhage | 10 |
low tidal | 10 |
acute sars | 10 |
pulmonary oedema | 10 |
ph value | 10 |
patients presenting | 10 |
high expression | 10 |
radiological findings | 10 |
preliminary data | 10 |
circulating blood | 10 |
malaria infection | 10 |
neurological signs | 10 |
mbl levels | 10 |
clinically significant | 10 |
probable bat | 10 |
creatinine clearance | 10 |
kg min | 10 |
sectional study | 10 |
severe thrombocytopenia | 10 |
adenovirus infection | 10 |
thromboembolic disease | 10 |
natriuretic peptide | 10 |
ill patient | 10 |
peritoneal cavity | 10 |
veterinary ophthalmologist | 10 |
multiple testing | 10 |
blood vessel | 10 |
portosystemic shunt | 10 |
nasopharyngeal aspirates | 10 |
wuhan clinical | 10 |
severe adverse | 10 |
immunodeficient patients | 10 |
tickborne infections | 10 |
cell transplantation | 10 |
convalescent patients | 10 |
severe pandemic | 10 |
antigen presentation | 10 |
high concentrations | 10 |
renal impairment | 10 |
adenovirus pneumonia | 10 |
cell deformability | 10 |
sars pneumonia | 10 |
blood clots | 10 |
extracellular fluid | 10 |
patients suffering | 10 |
mice infected | 10 |
septic patients | 10 |
year prospective | 10 |
tested positive | 10 |
several weeks | 10 |
iv slowly | 10 |
signaling pathway | 10 |
induced lung | 10 |
willebrand factor | 10 |
major role | 10 |
specific symptoms | 10 |
five cases | 10 |
hbv dna | 10 |
molecular biology | 10 |
dose intravenous | 10 |
allergic rhinitis | 10 |
mean airway | 10 |
rubber catheter | 10 |
portal area | 10 |
humanized mab | 10 |
label non | 10 |
hydrogen peroxide | 10 |
clinical syndromes | 10 |
small bowel | 10 |
fluid balance | 10 |
beneficial effects | 10 |
invasive pulmonary | 10 |
one year | 10 |
severe inflammatory | 10 |
lung inflammation | 10 |
may influence | 10 |
severe forms | 10 |
altered mental | 10 |
plasma inflammatory | 10 |
physiological conditions | 10 |
mental status | 10 |
mg day | 10 |
fluid overload | 10 |
ballooning degeneration | 10 |
oxygen inhalation | 10 |
york city | 10 |
blood tests | 10 |
hypotensive shock | 10 |
immunosorbent assay | 10 |
severe hypoxemia | 10 |
severe form | 10 |
cancer patients | 10 |
analyzed using | 10 |
potential treatment | 10 |
humoral responses | 10 |
better understand | 10 |
systolic blood | 10 |
interquartile range | 10 |
tracheal wash | 10 |
spread rapidly | 10 |
year period | 10 |
sickle cell | 10 |
data available | 10 |
literature review | 10 |
sporadic cases | 10 |
west africa | 10 |
global burden | 10 |
randomised controlled | 10 |
even death | 10 |
factor xii | 10 |
examination findings | 10 |
oxygenation index | 10 |
laboratory data | 10 |
plasma concentration | 10 |
syndrome patients | 10 |
outbreak associated | 10 |
early treatment | 10 |
living alone | 10 |
cardiovascular status | 10 |
late stages | 10 |
days post | 10 |
viral diseases | 10 |
preterm infants | 10 |
symptomatic treatment | 10 |
psychiatric disorders | 10 |
publication bias | 10 |
needle catheter | 10 |
noncardiogenic pulmonary | 10 |
likely due | 10 |
abdominal distension | 10 |
also showed | 10 |
flow ratio | 10 |
fracture site | 10 |
reduced mortality | 10 |
cell infiltration | 10 |
short time | 10 |
malignant progression | 10 |
considered statistically | 10 |
drug reactions | 10 |
poor clinical | 10 |
main causes | 10 |
peritoneal lavage | 10 |
respiratory droplets | 10 |
saudi arabia | 10 |
neurological manifestations | 10 |
previous reports | 10 |
observational cohort | 10 |
mab used | 10 |
clinical spectrum | 10 |
common cold | 10 |
lung lesions | 10 |
energy metabolism | 10 |
heparinized saline | 10 |
systemic hypertension | 10 |
pleural fluid | 10 |
ill sars | 10 |
one third | 10 |
clinical conditions | 10 |
bartonella infection | 10 |
energy expenditure | 10 |
environmental factors | 10 |
psychiatric symptoms | 10 |
antimicrobial therapy | 10 |
practice guidelines | 10 |
medical care | 9 |
membrane protein | 9 |
single center | 9 |
cranial nerve | 9 |
reverse transcriptase | 9 |
include fever | 9 |
plasmatic levels | 9 |
placebo group | 9 |
compared using | 9 |
increased incidence | 9 |
recently emerged | 9 |
remains unknown | 9 |
among women | 9 |
two major | 9 |
body fluid | 9 |
pulmonary involvement | 9 |
healthy donors | 9 |
radiation therapy | 9 |
factor alpha | 9 |
vivax infection | 9 |
cell apoptosis | 9 |
airway epithelium | 9 |
health status | 9 |
early identification | 9 |
two years | 9 |
often cause | 9 |
different degrees | 9 |
less likely | 9 |
left atrial | 9 |
i iii | 9 |
highly expressed | 9 |
ct value | 9 |
adult asthma | 9 |
infection association | 9 |
emergency management | 9 |
also shown | 9 |
clinical response | 9 |
least two | 9 |
six months | 9 |
almost exclusively | 9 |
commonly seen | 9 |
increased capillary | 9 |
white tape | 9 |
mechanisms involved | 9 |
anesthetic depth | 9 |
main cause | 9 |
immunocompromised hosts | 9 |
motor neuron | 9 |
sars epidemic | 9 |
clinical sign | 9 |
tracheal aspirates | 9 |
rescue therapy | 9 |
main protease | 9 |
prophylactic anticoagulation | 9 |
primary immunodeficiencies | 9 |
confidence intervals | 9 |
conventional mechanical | 9 |
activator inhibitor | 9 |
sterile gloves | 9 |
clinical case | 9 |
significant association | 9 |
tidal carbon | 9 |
treat covid | 9 |
asymptomatic cases | 9 |
calcium gluconate | 9 |
arterial oxygenation | 9 |
severe inflammation | 9 |
two types | 9 |
blood films | 9 |
clot formation | 9 |
protein levels | 9 |
pneumonia patients | 9 |
newborn infants | 9 |
first described | 9 |
related acute | 9 |
recent meta | 9 |
electrolyte imbalances | 9 |
nonstructural protein | 9 |
massive release | 9 |
three types | 9 |
viral activity | 9 |
aspiration pneumonitis | 9 |
ncov infection | 9 |
myeloid cells | 9 |
taken together | 9 |
patients present | 9 |
neurological sequelae | 9 |
flow nasal | 9 |
following conditions | 9 |
moderate group | 9 |
alveolar macrophages | 9 |
hepatocellular carcinoma | 9 |
hubei province | 9 |
rib fractures | 9 |
respiratory complications | 9 |
prothrombin activity | 9 |
longitudinal studies | 9 |
improve outcomes | 9 |
neutrophilic inflammation | 9 |
granulomatous disease | 9 |
adhesive tape | 9 |
survival time | 9 |
following formula | 9 |
merkel cell | 9 |
genomic characterisation | 9 |
plasma concentrations | 9 |
people living | 9 |
serious adverse | 9 |
intravenous injection | 9 |
institutional review | 9 |
lumbar puncture | 9 |
require mechanical | 9 |
health authorities | 9 |
viral etiology | 9 |
patients recovered | 9 |
affected areas | 9 |
severely affected | 9 |
adverse drug | 9 |
virus origins | 9 |
unfractionated heparin | 9 |
least days | 9 |
international guidelines | 9 |
intermediate layer | 9 |
endemic regions | 9 |
therapeutic effect | 9 |
prognostic indicator | 9 |
specific immune | 9 |
naturally occurring | 9 |
often occurs | 9 |
infectious agent | 9 |
traumatic brain | 9 |
ideal body | 9 |
significantly decreased | 9 |
leading cause | 9 |
vascular dilation | 9 |
pathological features | 9 |
acute abdominal | 9 |
respiratory virus | 9 |
progressive respiratory | 9 |
guidance statement | 9 |
also present | 9 |
hbv related | 9 |
active bleeding | 9 |
published studies | 9 |
chb patients | 9 |
pulmonary inflammation | 9 |
base excess | 9 |
south america | 9 |
sedimentation rate | 9 |
consider cytokine | 9 |
effect model | 9 |
mycobacterium tuberculosis | 9 |
lectin pathway | 9 |
severe symptom | 9 |
transitional cell | 9 |
among others | 9 |
sample collection | 9 |
neutrophil count | 9 |
one week | 9 |
cardiac dysfunction | 9 |
sodium concentration | 9 |
tyrosine kinase | 9 |
chronic health | 9 |
cause clinical | 9 |
mediated immunity | 9 |
lateral recumbency | 9 |
negative pressure | 9 |
linked immunosorbent | 9 |
inflammatory monocyte | 9 |
medical therapy | 9 |
following infection | 9 |
fusion protein | 9 |
renal insufficiency | 9 |
body fluids | 9 |
pleural cavity | 9 |
patent airway | 9 |
severe eosinophilic | 9 |
secondary bacterial | 9 |
clinical predictors | 9 |
nuclear factor | 9 |
prevent infection | 9 |
case definitions | 9 |
surgical correction | 9 |
term use | 9 |
clinical evidence | 9 |
fda label | 9 |
thermal burns | 9 |
high affinity | 9 |
children admitted | 9 |
stranded rna | 9 |
elevated il | 9 |
way stopcock | 9 |
retinal detachment | 9 |
inspired oxygen | 9 |
bacterial culture | 9 |
commonly reported | 9 |
positive results | 9 |
cardiopulmonary bypass | 9 |
inflammatory factors | 9 |
acute malaria | 9 |
three groups | 9 |
adenovirus infections | 9 |
associated encephalopathy | 9 |
corona virus | 9 |
also revealed | 9 |
hepatic lobules | 9 |
th th | 9 |
following sars | 9 |
fulminant liver | 9 |
storm syndromes | 9 |
like symptoms | 9 |
particularly important | 9 |
factors influencing | 9 |
volume expansion | 9 |
term prognosis | 9 |
often difficult | 9 |
new cases | 9 |
human cases | 9 |
routine clinical | 9 |
immediate treatment | 9 |
meld score | 9 |
quantitative chest | 9 |
low doses | 9 |
aspergillus fumigatus | 9 |
organ function | 9 |
intrinsic renal | 9 |
usually associated | 9 |
common type | 9 |
severe clinical | 9 |
case study | 9 |
may explain | 9 |
antibody production | 9 |
wbc count | 9 |
medical treatment | 9 |
pulmonary parenchymal | 9 |
pneumonia severity | 9 |
four factors | 9 |
death rate | 9 |
cardiovascular support | 9 |
still remains | 9 |
supraventricular tachycardia | 9 |
structural protein | 9 |
days following | 9 |
structural basis | 9 |
patients reported | 9 |
immunol doi | 9 |
aldosterone system | 9 |
asymptomatic infection | 9 |
tolerate oral | 9 |
bal cytology | 9 |
immune deficiency | 9 |
diseases society | 9 |
permissive hypercapnia | 9 |
electrolyte status | 9 |
occurred within | 9 |
mannosebinding lectin | 9 |
diagnostic peritoneal | 9 |
bacterial pathogens | 9 |
therapeutic approach | 9 |
flow rate | 9 |
muscle weakness | 9 |
showed higher | 9 |
barrier function | 9 |
safety profile | 9 |
intravenous extension | 9 |
renal injury | 9 |
cytokine profile | 9 |
density lipoprotein | 9 |
health system | 9 |
dose corticosteroids | 9 |
two independent | 9 |
median survival | 9 |
chronic rhinosinusitis | 8 |
develop acute | 8 |
important aspect | 8 |
understanding sars | 8 |
passive range | 8 |
nipah virus | 8 |
two doses | 8 |
borrelia burgdorferi | 8 |
hypersensitivity reaction | 8 |
people worldwide | 8 |
mannose binding | 8 |
immune pathways | 8 |
interferon responses | 8 |
significant improvement | 8 |
po bid | 8 |
severe renal | 8 |
function may | 8 |
two weeks | 8 |
randomised trial | 8 |
review will | 8 |
adverse outcomes | 8 |
high serum | 8 |
intravenous administration | 8 |
aerosol inhalation | 8 |
mucous membrane | 8 |
will improve | 8 |
treatment effects | 8 |
patients show | 8 |
severe bleeding | 8 |
th cytokines | 8 |
suspected cases | 8 |
significant decrease | 8 |
affected patients | 8 |
multiple factors | 8 |
cardiac contractility | 8 |
disease pathogenesis | 8 |
concentrated human | 8 |
acute pulmonary | 8 |
tissue necrosis | 8 |
major cause | 8 |
first day | 8 |
neurologic examination | 8 |
bilateral lung | 8 |
may vary | 8 |
pericardial effusion | 8 |
imaging features | 8 |
chronic bronchitis | 8 |
respiratory pathogens | 8 |
unclear whether | 8 |
liver tissues | 8 |
cell necrosis | 8 |
proven protease | 8 |
peripheral lymphocyte | 8 |
lung diseases | 8 |
term safety | 8 |
airway remodelling | 8 |
magnetic resonance | 8 |
drug report | 8 |
five patients | 8 |
chronic hepatic | 8 |
pulmonary angiography | 8 |
th day | 8 |
clinical care | 8 |
vertical transmission | 8 |
iv tid | 8 |
insufficient ventilation | 8 |
systematic reviews | 8 |
sepsis campaign | 8 |
time activity | 8 |
amoy gardens | 8 |
asthma phenotypes | 8 |
gene polymorphisms | 8 |
toxicity includes | 8 |
first time | 8 |
respiratory effort | 8 |
improved survival | 8 |
signaling pathways | 8 |
exploratory laparotomy | 8 |
increased viral | 8 |
coronavirus sars | 8 |
studies suggest | 8 |
cerebral hernia | 8 |
transfusion reaction | 8 |
related liver | 8 |
will increase | 8 |
specific cd | 8 |
human leptospirosis | 8 |
biochemistry profile | 8 |
supportive therapy | 8 |
control groups | 8 |
immunoglobulin products | 8 |
blood sugar | 8 |
room air | 8 |
sodium phosphate | 8 |
pneumonia groups | 8 |
patient care | 8 |
epidemiological characteristics | 8 |
invasive aspergillosis | 8 |
antimicrobial agents | 8 |
less commonly | 8 |
local anesthetics | 8 |
medical emergency | 8 |
ct imaging | 8 |
first cases | 8 |
incidence rate | 8 |
clear evidence | 8 |
candidate vaccines | 8 |
serum amylase | 8 |
commonly observed | 8 |
ground glass | 8 |
wearing sterile | 8 |
human sars | 8 |
predictive factors | 8 |
humidified oxygen | 8 |
nan doi | 8 |
deceased patients | 8 |
treat hyperthermia | 8 |
cases among | 8 |
commonly found | 8 |
frequently used | 8 |
operating characteristic | 8 |
required mechanical | 8 |
mouse models | 8 |
myasthenia gravis | 8 |
effective antiviral | 8 |
acute intrinsic | 8 |
may manifest | 8 |
mild symptoms | 8 |
play important | 8 |
burst activity | 8 |
also play | 8 |
arterial thromboembolism | 8 |
coronavirus pathogenesis | 8 |
receiver operating | 8 |
humoral response | 8 |
aseptic necrosis | 8 |
subcutaneous tissue | 8 |
may take | 8 |
well described | 8 |
inhaled nitric | 8 |
pit viper | 8 |
persistent infection | 8 |
progress rapidly | 8 |
routine blood | 8 |
absolutely contraindicated | 8 |
adjunct therapy | 8 |
blood smears | 8 |
third day | 8 |
one hand | 8 |
different populations | 8 |
bcg vaccination | 8 |
cardiac silhouette | 8 |
directed therapy | 8 |
distal end | 8 |
thoracic duct | 8 |
hospitalization priority | 8 |
patients following | 8 |
previously shown | 8 |
increased expression | 8 |
primary outcome | 8 |
potential benefits | 8 |
available evidence | 8 |
igg antibody | 8 |
may benefit | 8 |
fda drug | 8 |
nasal catheter | 8 |
hematopoietic stem | 8 |
dna vaccines | 8 |
hemorrhagic shock | 8 |
derived macrophages | 8 |
creactive protein | 8 |
one month | 8 |
vivo study | 8 |
coronary heart | 8 |
lung volume | 8 |
face mask | 8 |
review board | 8 |
airway bleeding | 8 |
older patients | 8 |
opportunistic infections | 8 |
expression levels | 8 |
gastrointestinal ulceration | 8 |
worse prognosis | 8 |
blood ph | 8 |
publisher full | 8 |
lung involvement | 8 |
kg ideal | 8 |
cutaneous manifestations | 8 |
ace gene | 8 |
borne diseases | 8 |
term outcomes | 8 |
plr levels | 8 |
recent review | 8 |
adjunctive therapy | 8 |
within normal | 8 |
artificial ventilation | 8 |
following criteria | 8 |
specific conditions | 8 |
refractory septic | 8 |
upper limit | 8 |
acute management | 8 |
epidemiological studies | 8 |
cytokine il | 8 |
second intention | 8 |
thoracic auscultation | 8 |
rapid progression | 8 |
entry depends | 8 |
prerenal azotemia | 8 |
cns disease | 8 |
levels may | 8 |
statistical difference | 8 |
erythrocyte sedimentation | 8 |
different groups | 8 |
ongoing hemorrhage | 8 |
prognostic factor | 8 |
azole antifungals | 8 |
bacterial meningitis | 8 |
see also | 8 |
interstitial pneumonia | 8 |
large sample | 8 |
much lower | 8 |
endothelial growth | 8 |
hour iv | 8 |
infect dis | 8 |
see sections | 8 |
viral fusion | 8 |
pcr testing | 8 |
antiviral agents | 8 |
normal blood | 8 |
respiratory problems | 8 |
pulmonary vasculature | 8 |
carbon monoxide | 8 |
blood type | 8 |
like illness | 8 |
preliminary study | 8 |
receiving mg | 8 |
often reveals | 8 |
among cases | 8 |
killer cell | 8 |
fatality rates | 8 |
progenitor cells | 8 |
fluid deficit | 8 |
plasma level | 8 |
intoxication include | 8 |
clinical evaluation | 8 |
rna synthesis | 8 |
underlying causes | 8 |
abdominal paracentesis | 8 |
viral disease | 8 |
wound exudates | 8 |
airborne transmission | 8 |
intestinal endotoxemia | 8 |
relatively high | 8 |
international consensus | 8 |
label use | 8 |
viral pathogens | 8 |
intermediate dose | 8 |
severe patient | 8 |
many factors | 8 |
cov infections | 8 |
improved clinical | 8 |
respiratory compromise | 8 |
hospitalised patients | 8 |
line treatment | 8 |
among adults | 8 |
mortality associated | 8 |
low risk | 8 |
abdominal effusion | 8 |
lymphocyte subset | 8 |
perfusion parameters | 8 |
jak inhibitor | 8 |
nasopharyngeal swabs | 8 |
circulating immune | 8 |
patients required | 8 |
endothelial dysfunction | 8 |
patients received | 8 |
clinical assessment | 8 |
including il | 8 |
tocilizumab treatment | 8 |
survival rates | 8 |
emerging viral | 8 |
mortality risk | 8 |
patients require | 8 |
treat ingestion | 8 |
small animals | 8 |
available data | 8 |
patients affected | 8 |
cl pro | 8 |
three times | 8 |
failure may | 8 |
based study | 8 |
wide variety | 8 |
generation cephalosporin | 8 |
patients clinical | 8 |
requiring intensive | 8 |
mainland china | 8 |
blood groups | 8 |
infections may | 8 |
intracranial hypertension | 8 |
patients within | 8 |
limited data | 8 |
position paper | 8 |
supportive treatment | 8 |
hyaline membrane | 8 |
promote diuresis | 8 |
radiographs may | 8 |
become infected | 8 |
chloroquine hydroxychloroquine | 8 |
nasal cpap | 8 |
cumulative dose | 8 |
chronic granulomatous | 8 |
maintain renal | 8 |
pseudomonas aeruginosa | 8 |
surface area | 8 |
eosinophilic inflammation | 8 |
failure due | 8 |
teaching hospital | 8 |
current state | 8 |
monitor urine | 8 |
patient groups | 8 |
dehydrogenase level | 8 |
therapeutic options | 8 |
previous study | 8 |
viral protein | 8 |